Dr. David Andes is a faculty member and chief of the Division of Infectious Disease within the Department of Medicine, and also has an appointment in the Department of Medical Microbiology and Immunology. He holds the William A. Craig Endowed Professorship, and directs the Wisconsin Antimicrobial Drug Discovery and Development NIH Center of Excellence.
Dr. Andes is frequently acknowledged for his research contributions in the areas of infectious disease and drug resistance. He has received a National Institutes of Health Mentored Clinical Scientist Development Award, an American Society for Microbiology ICAAC Young Investigator Award, a University of Missouri Alumni Award, a University of Wisconsin Department of Medicine Puestow Research Award and Rankin Research Award, and the Billy Cooper Award from the Medical Mycological Society of the Americas, To 1% highly cited researcher in Web of Science, American Society of Health-system Pharmacy Foundation – Innovation in Pharmacy Services Award.
Dr. Andes is a Fellow of the Infectious Diseases Society of America, the American Academy of Microbiology, the American Association for the Advancement of Science, and the European Conferation of Medical Mycology. He is the past president of the International Society of Antimicrobial Pharmacology, and has been selected as a member of the American Society of Clinical Investigation, the Clinical Laboratory Standards Institute Antifungal Committee, USCAST, Faculty of 1000, the Mycoses Study Group (MSG) Steering Committee, and the American Association of Physicians. He is an editor of Journal of Infectious Diseases, past editor for Antimicrobial Agents and Chemotherapy and is on the editorial boards of ten prominent journals.
Dr. Andes’ clinical interests include fungal infections, transplant infectious diseases, antimicrobial pharmacokinetics and pharmacodynamics, and travel medicine.
View Dr. David Andes' publications on NCBI MyBibliography
View Dr. David Andes' publications on Google Scholar
Dr. Andes' research programs are multidisciplinary and strive to identify strategies to combat antimicrobial (especially antifungal) drug resistance. His study tactics span from the bench to the clinic, including identifying new resistance mechanisms, defining new antimicrobial drug targets, delineating the optimal dosing strategies for treatment of drug resistant infections, and clinical trial study of epidemiology of drug resistance epidemiology. Dr. Andes' research efforts have been continuously funded by the NIH since 2001. He has published his research in more than 400 papers, which have been cited more than 51,000 times by other scientists. His publications provide much of the scientific underpinning for treatment of drug-resistant infections. The results of these studies have been translated into management guidelines and his scientific approaches are being utilized to identify and develop the next generation of antimicrobial drugs.